1. Home
  2. CTRM vs LEXX Comparison

CTRM vs LEXX Comparison

Compare CTRM & LEXX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Castor Maritime Inc.

CTRM

Castor Maritime Inc.

HOLD

Current Price

$1.97

Market Cap

21.2M

ML Signal

HOLD

Logo Lexaria Bioscience Corp.

LEXX

Lexaria Bioscience Corp.

HOLD

Current Price

$1.08

Market Cap

22.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CTRM
LEXX
Founded
2016
2004
Country
Cyprus
Canada
Employees
N/A
N/A
Industry
Marine Transportation
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
21.2M
22.7M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
CTRM
LEXX
Price
$1.97
$1.08
Analyst Decision
Strong Buy
Analyst Count
0
1
Target Price
N/A
$4.00
AVG Volume (30 Days)
37.7K
207.6K
Earning Date
11-07-2025
01-09-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$67,859,415.00
$705,923.00
Revenue This Year
N/A
$46.98
Revenue Next Year
N/A
$17.26
P/E Ratio
N/A
N/A
Revenue Growth
N/A
49.85
52 Week Low
$1.84
$0.77
52 Week High
$3.64
$2.85

Technical Indicators

Market Signals
Indicator
CTRM
LEXX
Relative Strength Index (RSI) 48.36 55.22
Support Level $1.85 $1.00
Resistance Level $1.99 $1.15
Average True Range (ATR) 0.07 0.08
MACD 0.01 -0.00
Stochastic Oscillator 48.83 59.50

Price Performance

Historical Comparison
CTRM
LEXX

About CTRM Castor Maritime Inc.

Castor Maritime Inc is a provider of seaborne transportation services for dry bulk cargo, including iron ore, coal, grain, steel products, fertilizers, cement, bauxite, sugar, and scrap metal, among others. The firm operates under three reportable segments namely (i) the dry bulk segment (ii) the containership segment and (iii) the asset management segment. It generates maximum revenue from the Dry bulk segment.

About LEXX Lexaria Bioscience Corp.

Lexaria Bioscience Corp's patented drug delivery technology, DehydraTECH improves the way active pharmaceutical ingredients enter the bloodstream by promoting more effective oral delivery. DehydraTECH can increase bio-absorption with cannabinoids and nicotine by 5-10x and, in some instances with cannabinoids by as much as 27x compared to standard industry formulations, reduce the time of onset from 1-2 hours to minutes, and mask unwanted tastes. DehydraTECH has also evidenced an ability to deliver some drugs more effectively across the blood-brain barrier. The company has four reportable segments: Intellectual Property Licensing which generates maximum revenue, B2B Production, Research and Development, and Corporate. Geographically, it derives revenue from the United States and Canada.

Share on Social Networks: